WAVEMAN · COMPANY

ROIV · Roivant Sciences Ltd.

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

ROIV

Name: Roivant Sciences Ltd. (ROIV) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Roivant Sciences Ltd.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001635088

CONGRESS · 1FORM 144 · 14☆ WATCH

INSIDER NET · 180D

-$277.1M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

300

13F, latest reported quarter

REVENUE GROWTH

-71.6%

XBRL, annual

NET MARGIN

-3629.2%

CONVERSIONS · 180D

codes C/M, not in net · $13.1M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$277.1M over 180 days

-$247.5M over 90 days

below 99% of Pharma & Biotech

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

300 funds added or opened last quarter

more than 93% of Pharma & Biotech

REVENUE

-71.6% year over year

below 88% of Pharma & Biotech

MARGIN

-3629.2% net margin

below 96% of Pharma & Biotech

BUYBACKS

$206.7M repurchased, FY to 2026-06-30

more than 78% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$277.1M across 9 people in 180 days.

300 funds added or opened positions in the latest 13F quarter, of 500 holders.

1 member of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +175.9%

+175.9%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $277.1M sold by insiders over 180 days, 300 funds added last quarter, 1 Congress member(s) bought in 12 months, $99.4M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Roivant Sciences Ltd. insiders sold a net $277.1M of stock across 291 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

Venker Eric

President & Immunovant CEO

SELL

2026-08-28

166,182.0

$5.9M

Venker Eric

President & Immunovant CEO

SELL

2026-08-28

33,818.0

$1.2M

Sukhatme Mayukh

President & CIO

SELL

2026-08-21

144,756.0

$5.3M

Sukhatme Mayukh

President & CIO

SELL

2026-08-20

17,519.0

$653.5K

Sukhatme Mayukh

President & CIO

SELL

2026-08-19

172,899.0

$6.4M

291 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 286 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

FMR LLC

81,020,390.0 sh

$2.9B

BlackRock, Inc.

48,236,091.0 sh

$1.7B

MORGAN STANLEY

42,592,905.0 sh

$1.5B

QVT Financial LP

23,723,074.0 sh

$839.6M

VANGUARD CAPITAL MANAGEMENT LLC

22,123,198.0 sh

$782.9M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

Venker Eric

FILED 2026-08-28

$7.1M

MAYUKH SUKHATME

FILED 2026-08-21

$5.3M

MAYUKH SUKHATME

FILED 2026-08-20

$653.4K

MAYUKH SUKHATME

FILED 2026-08-19

$6.4M

MAYUKH SUKHATME

FILED 2026-08-18

$5.0M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Invesco Dorsey Wright Healthcare Momentum ETF

$5.6M POSITION · AS OF 2026-04-30

4.7%

AlphaCentric Life Sciences and Healthcare Fund

$1.3M POSITION · AS OF 2026-03-31

3.4%

Invesco S&P MidCap Momentum ETF

$130.5M POSITION · AS OF 2026-04-30

1.9%

Invesco Nasdaq Biotechnology ETF

$1.1M POSITION · AS OF 2026-02-28

1.5%

Anfield Enhanced Market ETF

$2.2M POSITION · AS OF 2026-04-30

1.5%

Health Sciences Trust

$2.6M POSITION · AS OF 2026-03-31

1.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2026-03	2025-03	2024-03	2023-03
REVENUE	$8.3M	$29.1M	$32.7M	$31.5M
OPERATING INCOME	$-515.1M	$-1.0B	$4.5B	$-906.8M
NET INCOME	$-397.9M	$-356.7M	$4.2B	$-1.1B
EPS (DILUTED)	-0.54	-0.24	5.23	-1.42
OPERATING CASH FLOW	$-750.3M	$-839.5M	$-765.3M	$-843.4M
CASH	$1.4B	$2.7B	$6.5B	$1.7B
LONG-TERM DEBT	—	—	$430.6M	$375.5M
BUYBACKS	—	$1.3B	$0	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE